ImmunityBio (IBRX) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 290.0% versus a gain of 4.7%. Over five years, NBIX leads with a +37.2% price change compared with +4.8% for IBRX. Neurocrine Biosciences is the larger company by market cap ($14.58 billion vs $10.33 billion), about 1.4 times the size, while ImmunityBio is growing revenue faster (+668.3% vs +21.4%).
Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | NBIX |
|---|---|---|
| Share price | $9.75 | $143.47 |
| Market cap | $10.33B | $14.58B |
| 1-day change | +0.62% | -1.40% |
| YTD return | +392.42% | +1.16% |
| 1-year return | +290.00% | +4.72% |
| 5-year return | +4.84% | +37.24% |
| P/E ratio (TTM) | — | 21.32 |
| Forward P/E | — | 12.08 |
| EPS (TTM) | $-0.97 | $6.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $2.86B |
| Revenue growth (YoY) | +668.31% | +21.45% |
| Net income (latest FY) | $-351.40M | $478.60M |
| Gross margin | 99.34% | 98.18% |
| Operating margin | -226.00% | 21.64% |
| Net margin | -310.18% | 16.73% |
| 52-week high | $12.43 | $186.12 |
| 52-week low | $1.95 | $122.14 |
| Distance from 52-week high | -21.56% | -22.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +30.77% | +44.48% |
| Average volume | 10.27M | 1.30M |
| Shares outstanding | 1.06B | 101.65M |
| Employees | 684 | 2,500 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed NBIX by 285.3 percentage points over the past year.
- Neurocrine Biosciences is more profitable, keeping 16.7 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +21.45%).
- The two companies sit in different sectors: ImmunityBio in Health Care and Neurocrine Biosciences in Healthcare.
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 2,500 employees
IBRX vs NBIX FAQ
Which is bigger, ImmunityBio or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.58B compared with $10.33B for ImmunityBio (IBRX).
Which stock has performed better over the past year, IBRX or NBIX?
IBRX returned +290.00% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Neurocrine Biosciences in the same industry?
No. ImmunityBio is in the Health Care sector, while Neurocrine Biosciences is in Healthcare.